The funding round was led by Archangels to support human trials of the BioCaptis device.
"BIOCAPTIVA is at the forefront of developing technology to transform liquid biopsy testing in cancer management. We are pleased to have raised these additional funds as the company enters its next stage of development, with the BioCaptis beginning its first in human trials. These trials will allow us to generate important data before the end of 2022. This will be a key step before starting regulatory trials in 2023 as we move towards our goal of unleashing the full potential of liquid biopsy in cancer management to improve patient outcomes."
NPIF Maven Equity Finance provided the capital to support product development and audience growth.
"This exciting, customer-centric business is a great addition to the Maven and NPIF portfolio. The business has great future ambitions and is fast becoming a key name within the fintech industry. We have been impressed by the quality of the management team and existing shareholder base."
The cannabis distributor secured £7.4m alongside a string of international acquisitions.
"Sana’s latest fundraising round and rapid growth clearly shows the appetite for a well-run, regulated legal cannabis market in Europe. With estimates of a million people in the UK potentially buying medicinal cannabis from the black market due to financial and legal barriers, accessible solutions like Sana are desperately needed."
The NFT platform raised funding from notable angel investors including Paul Forster to support its curated digital art marketplace.
"For artists, just as in the traditional art world, marketing and selling NFTs is a huge job and requires specialist knowledge and skills. It’s unlikely the world’s best digital artists will rise to the top if they also have to be world-class at web3 marketing in order to do so. We’re therefore helping artists join forces with people who really get it, leaving the artist to do what they do best – create amazing works!"
